MAP
VRNA

Moody Aldrich Partners’s Verona Pharma VRNA Stock Holding History

Moody Aldrich Partners’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-49,302
Closed -$4.66M – 207
2025
Q2 		$4.66M Sell
49,302
-47,301
-49% -$3.5M 0.9% 48
2025
Q1 		$6.13M Buy
96,603
+1,661
+2% +$99.4K 1.28% 20
2024
Q4 		$4.41M Sell
94,942
-157,810
-62% -$5.92M 0.82% 53
2024
Q3 		$7.27M Sell
252,752
-43,193
-15% -$1.06M 1.32% 20
2024
Q2 		$4.28M Sell
295,945
-18,967
-6% -$277K 0.83% 56
2024
Q1 		$5.07M Sell
314,912
-6,249
-2% -$108K 0.86% 45
2023
Q4 		$6.38M Sell
321,161
-33,676
-9% -$497K 1.15% 26
2023
Q3 		$5.78M Buy
354,837
+13,136
+4% +$253K 1.1% 34
2023
Q2 		$7.22M Sell
341,701
-9,969
-3% -$213K 1.4% 19
2023
Q1 		$7.06M Buy
351,670
+130,487
+59% +$2.82M 1.43% 16
2022
Q4 		$5.78M Sell
221,183
-6,806
-3% -$90.6K 1.17% 27
2022
Q3 		$2.33M Buy
+227,989
New +$1.92M 0.48% 69

Other funds holding VRNA

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Moody Aldrich Partners's VRNA Position: Q3 2025 in Review

Moody Aldrich Partners sold out of Verona Pharma (VRNA) in Q3 2025, closing a stake of 49,302 shares — an estimated $4.66M sold.

Moody Aldrich Partners first reported a position in VRNA in Q3 2022 and held it in 12 quarters. The position peaked at $7.27M in Q3 2024. 243 funds tracked by Wall St. Rank hold VRNA as of Q3 2025.

  • Moody Aldrich Partners reported no remaining Verona Pharma position as of Q3 2025 after selling out during the quarter.
  • Moody Aldrich Partners sold 49,302 Verona Pharma shares in Q3 2025, an estimated $4.66M.
  • Moody Aldrich Partners first reported a position in Verona Pharma in Q3 2022 and held it in 12 quarters.
  • Moody Aldrich Partners's Verona Pharma position peaked at $7.27M in Q3 2024.
  • 243 funds tracked by Wall St. Rank held Verona Pharma as of Q3 2025.

Based on Moody Aldrich Partners's 13F filing for Q3 2025, filed 21 Oct 2025.